BGB-3245+Panitumumab in Advanced/Metastatic RAS mutant CRC & Pancreatic Ductal Cancers (MapKure)

What is the Purpose of this Study?

We are doing this study to see if the combination of an experimental drug called BGB-3245 (the study drug) and panitumumab is a safe and effective option for patients who have colorectal or pancreatic cancer with an RAS mutation.

What is the Condition Being Studied?

Advanced or Metastatic RAS Mutant Colorectal Cancer and Pancreatic Ductal Cancers

Who Can Participate in the Study?

Adults ages 18+ who:

  • Are diagnosed with advanced or metastatic RAS mutant colorectal cancer; OR
  • Are diagnosed with RAS mutant pancreatic ductal cancer

For more information about who can join this study, please contact the study team at gi-oncology-cru@dm.duke.edu or 919-668-1861.

Age Group
Adults

What is Involved?

If you choose to join this study, you will:

  • Take the study drug in combination with panitumumab
  • Have a tumor biopsy done, if necessary
  • Have blood draws
  • Have imaging scans (CT or MRI)

Study Details

Full Title
A Phase 1b, Open-Label, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 with Panitumumab in Patients with Advanced or Metastatic RAS mutant Colorectal and Pancreatic Ductal Cancers
Principal Investigator
Professor of Medicine
Protocol Number
IRB: PRO00114943
NCT: NCT06194877
Phase
Phase I
ClinicalTrials.gov
Enrollment Status
OPEN TO ACCRUAL